clexane forte enoxaparin sodium 120mg/0.8ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 120 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 20mg/0.2ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 20 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
enoxaparin sandoz 2000 iu (20 mg) 0.2 ml solution for injection in pre-filled syringe
novartis corporation (malaysia) sdn. bhd. - enoxaparin sodium -
enoxaparin sodium ledraxen 10,000 iu (100 mg)/1 ml, solution for injection in pre-filled syringe
venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
enoxaparin sodium ledraxen 2,000 iu (20 mg)/0.2 ml, solution for injection in pre-filled syringe
venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
enoxaparin sodium ledraxen 4,000 iu (40 mg)/0.4 ml, solution for injection in pre-filled syringe
venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
enoxaparin sodium ledraxen 6,000 iu (60 mg)/0.6 ml, solution for injection in pre-filled syringe
venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
enoxaparin sodium ledraxen 8,000 iu (80 mg)/0.8 ml, solution for injection in pre-filled syringe
venipharm - enoxaparin sodium - solution for injection in pre-filled syringe - enoxaparin
clexane forte enoxaparin sodium 150mg/1ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 150 mg - injection, solution - excipient ingredients: nitrogen; water for injections - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).
clexane enoxaparin sodium 100mg/1ml injection syringe
sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).